Hills Bank & Trust Co Has $720,000 Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Hills Bank & Trust Co trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 64.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,012 shares of the medical equipment provider’s stock after selling 14,826 shares during the quarter. Hills Bank & Trust Co’s holdings in Zimmer Biomet were worth $720,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ZBH. Key Financial Inc boosted its holdings in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the period. Root Financial Partners LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at about $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at about $32,000. Finally, Grove Bank & Trust boosted its holdings in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on ZBH shares. Citigroup cut their price objective on shares of Zimmer Biomet from $98.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Finally, UBS Group reissued a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $102.80.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $83.73 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The stock has a market capitalization of $16.20 billion, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 1.94 and a beta of 0.48. The stock has a fifty day moving average of $89.60 and a 200-day moving average of $91.52.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.Zimmer Biomet’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.